Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 14/20 | 0.73 |
| ▸ | GNRHR | P30968 | 1/20 | 0.62 |
| ▸ | MC4R | P32245 | 2/20 | 0.62 |
| ▸ | MC5R | P33032 | 2/20 | 0.62 |
| ▸ | MC3R | P41968 | 2/20 | 0.62 |
| ▸ | MC1R | Q01726 | 2/20 | 0.62 |
| ▸ | NPY1R | P25929 | 1/20 | 0.61 |
| ▸ | NPY2R | P49146 | 1/20 | 0.61 |
| ▸ | NPY4R | P50391 | 1/20 | 0.61 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.61 |
| ▸ | CALCA | P06881 | 1/20 | 0.59 |
| ▸ | PTH1R | Q03431 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29860804 | 0.87 | CXCR4 (0.74) | CXCR4GNRHRMC4RMC5RMC3R | |
| SCHEMBL29430129 | 0.87 | CXCR4 (0.74) | CXCR4GNRHRMC4RMC5RMC3R | |
| SCHEMBL15147203 | 0.86 | F2 (0.60) | CXCR4MC4RMC5RMC3RMC1R | |
| SCHEMBL29462904 | 0.86 | CXCR4 (0.83) | CXCR4GNRHR | |
| SCHEMBL29491173 | 0.85 | C5AR1 (0.65) | CXCR4GNRHR | |
| SCHEMBL30646334 | 0.85 | CXCR4 (0.63) | CXCR4NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL29421992 | 0.84 | CXCR4 (0.66) | CXCR4GNRHRMC4RMC5RMC3R | |
| SCHEMBL29689766 | 0.84 | CXCR4 (0.66) | CXCR4GNRHRMC4RMC5RMC3R | |
| SCHEMBL30633418 | 0.84 | DPP3 (0.60) | CXCR4 | |
| SCHEMBL31278597 | 0.83 | CCKBR (0.58) | CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025264811-A1 | COMPOSITION AND METHODS FOR CONTROLLED RECRUITMENT OF ANALYTES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2025-12-26 | — | — | WO | claimed |
| EP-3467509-B1 | CNS ANTIGEN-SPECIFIC B CELL, T CELL AND ANTIBODY ASSAYS AND THEIR USES IN DIAGNOSIS AND TREATMENT OF MULTIPLE SCLEROSIS | CELLULAR TECH LTD (US) | 2025-11-26 | — | — | EP | disclosed |
| US-20250288654-A1 | TOLERANCE-INDUCING CONSTRUCTS AND COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF IMMUNE DISORDERS | Nykode Therapeutics ASA (NO) | 2025-09-18 | — | — | US | disclosed |
| EP-4615980-A1 | CO-EXPRESSION OF CONSTRUCTS AND POLYPEPTIDES | Nykode Therapeutics ASA (NO) | 2025-09-17 | — | — | EP | disclosed |
| US-20250276981-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. | 2025-09-04 | — | — | US | disclosed |
| US-20250195632-A1 | TOLERANCE-INDUCING CONSTRUCTS AND COMPOSITION AND THEIR USE FOR THE TREATMENT OF IMMUNE DISORDERS | Nykode Therapeutics ASA (NO) | 2025-06-19 | — | — | US | disclosed |
| EP-4536658-A1 | 1,8-NAPHTHYRIDIN-2-ONE HETEROBIFUNCTIONAL BCL6 DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-4536649-A1 | QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-4536650-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| WO-2025049968-A1 | TRICYCLIC QUINOLONE AND 1,8-NAPHTHYRIDIN-2-ONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-03-06 | — | — | WO | disclosed |
| CN-110064049-B | Peptide conjugate particles | 西北大学 | 2024-02-09 | — | — | CN | disclosed |
| CN-117377483-A | Tolerance-inducing constructs and compositions and their use in the treatment of immune disorders | 耐考德治疗股份有限公司 | 2024-01-09 | — | — | CN | disclosed |
| CN-117355326-A | Co-expression of constructs and immunosuppressive compounds | 耐考德治疗股份有限公司 | 2024-01-05 | — | — | CN | disclosed |
| WO-2023244918-A1 | QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023244917-A1 | 1,8-NAPHTHYRIDIN-2-ONE HETEROBIFUNCTIONAL BCL6 DEGRADERS | Treeline Biosciences, Inc. (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023240038-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2022238395-A1 | TOLERANCE-INDUCING CONSTRUCTS AND COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF IMMUNE DISORDERS | Nykode Therapeutics ASA (NO) | 2022-11-17 | — | — | WO | disclosed |
| WO-2022238432-A2 | CO-EXPRESSION OF CONSTRUCTS AND IMMUNOINHIBITORY COMPOUNDS | Nykode Therapeutics ASA (NO) | 2022-11-17 | — | — | WO | disclosed |
| WO-2022238402-A1 | TOLERANCE-INDUCING CONSTRUCTS AND COMPOSITION AND THEIR USE FOR THE TREATMENT OF IMMUNE DISORDERS | Nykode Therapeutics ASA (NO) | 2022-11-17 | — | — | WO | disclosed |
| US-11340224-B2 | Whole brain lysate antigen-specific memory B cell and antibody assays in multiple sclerosis | CELLULAR TECHNOLOGY LIMITED (US) | 2022-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250276981-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | BCL6, BCL6B, BCOR | CXCR4 3203/4885GNRHR 3591/4885MC4R 2808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.